KDR and cancer: This antiangiogenic activity, generated by receptor binding but only weak receptor activation (Cebe Suarez et al, 2006) and inhibition of downstream VEGF-R2 signalling, has led to the hypothesis that VEGF165b, or manipulation of C-terminal VEGF splicing to enhance more distal splicing, may be useful therapeutic tools in cancer.